openPR Logo
Press release

The medical device CRO market is estimated to be worth USD 15.7 billion in 2030, predicts Roots Analysis

11-17-2020 05:54 PM CET | Health & Medicine

Press release from: Roots Analysis

The medical device CRO market is estimated to be worth USD 15.7

Advances in the medical device industry have led to a substantial increase in developmental complexity, clinical trial conduct, and stringency of regulatory review, causing sponsors to rely on the technical and regulatory affairs management expertise of CROs

Roots Analysis is pleased to announce the publication of its recent study, titled, “Medical Device CRO Market (2nd Edition), 2020-2030”.

For more information please click on the following link:
https://www.rootsanalysis.com/reports/view_document/medical-device-cros-market/226.html

The report features an extensive study of the current market landscape and future opportunities of contract research service providers focused on medical devices. The study also features an in-depth analysis, highlighting the capabilities of the various stakeholders engaged in this domain, across different regions of the globe. In addition to other elements, the study includes:
A detailed review of the overall landscape of medical device CROs.
An elaborate discussion on the various guidelines established by major regulatory bodies for medical device approval across North America, Europe, and Asia-Pacific and rest of the world.
Elaborate profiles of key players that specialize in offering services for both clinical and preclinical stage development of medical devices.
An analysis highlighting the key performance indicators used by sponsor companies to evaluate service providers engaged in this domain
A competitive benchmarking, highlighting the key focus areas of small, mid-sized and large companies, comparing their existing capabilities within and beyond their respective peer groups.
A detailed brand positioning analysis of leading industry players (shortlisted on the basis of strength of service portfolio).
A detailed geographical clinical trial analysis of ongoing and planned studies related to medical devices.
A detailed analysis of the mergers and acquisitions that have taken place in this domain during the period 2015-2020.
A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing contract research services to medical device developers.
A discussion on affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the industry’s evolution.
An elaborate discussion on the future opportunities / trends for the medical device outsourcing market that are likely to influence the growth of this domain over the coming years.
A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
Phase of Development
Clinical
Preclinical

Types of Preclinical Services Offered
Biocompatibility testing
Sterility and microbiology testing
Material characterization and analytical services
Others

Types of Clinical Services Offered
Clinical trial management
Data management
Regulatory affairs management
Consulting
Others

Device Class
Class I medical devices
Class II medical devices
Class III medical devices

Target Therapeutic Area
CNS disorders
Cardiovascular disorders
Oncological disorders
Bone disorders
Respiratory disorders
Pain management disorders
Ophthalmic disorders
Psychological disorders
Metabolic disorders
Others

Key Geographical Regions
North America
Europe
Asia-Pacific
Rest of the World

For more information please click on the following link:
https://www.rootsanalysis.com/reports/view_document/medical-device-cros-market/226.html

Transcripts of interviews held with the following senior level representatives of stakeholder companies
Lajos Sarosi (Chief Executive Officer and Co-founder, HungaroTrial)
Christopher Rupp (Vice President of Global Marketing and Commercial Operations, NAMSA)
Christian Wolflehner (General Manager, CW Research & Management)
Troy Mccall (Chief Operating Officer, CROMSOURCE)
Nazish Urooj (Senior manager, Medical & Clinical Operations, Metrics Research)
C. Omprakash (Technical Director and Partner, Vyomus Consulting)
Tania Persson (Director of Business Development, A+ Science)
Alexa Foltin-Mertgen (Business Development Manager, AtoZ-CRO)

Key companies covered in the report
Avania (formerly known as Factory CRO)
Charles River Laboratories
Clinlogix
CROMSOURCE
CSSi LifeSciences™
Eurofins Medical Device Testing
genae
IMARC Research
IQVIA
Medpace
NAMSA
Qserve Group
Regulatory and Clinical Research Institute (now a part of Covance)
WuXi AppTec

For more information please click on the following link:
https://www.rootsanalysis.com/reports/view_document/medical-device-cros-market/226.html

Other Recent Offerings
1. Contract Regulatory Affairs Management Market for Medical Devices, 2019-2030
2. Medical Device Labels Manufacturing Market, 2019 - 2030
3. Medical Device Contract Manufacturing Market, 2019-2030

Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

Contact:
Gaurav Chaudhary
gaurav.chaudhary@rootsanalysis.com

Roots Analysis
A430, 4th Floor,
Bestech Business Towers, Sector 66, Mohali, India
sales@rootsanalysis.com
+1 (415) 800 3415
+44 (122) 391 1091
Web: https://www.rootsanalysis.com/
LinkedIn: https://in.linkedin.com/company/roots-analysis
Twitter: https://twitter.com/RootsAnalysis

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release The medical device CRO market is estimated to be worth USD 15.7 billion in 2030, predicts Roots Analysis here

News-ID: 2189048 • Views:

More Releases from Roots Analysis

Proteomics Market CAGR To Be 7.9% % by 2035, Due To The Growing Adoption of Proteomics Solutions| Roots Analysis
Proteomics Market CAGR To Be 7.9% % by 2035, Due To The Growing Adoption of Prot …
According to our latest market report "Proteomics Market" by Type of Offering, Type of Instrument / Technology, Type of Reagent, Type of Proteomics Service, Application Area, End-users, Type of Operation and Geography: Industry Trends and Global Forecasts, Till 2035", the global protein expression market, valued at USD 2.7 billion in 2024, is estimated to reach USD 3.0 billion in 2025 and USD 6.3 billion by 2035, representing a CAGR of
Industrial Robotics Market to Reach USD 39.03 Billion by 2035, Driven by Rising Automation Demand Across Manufacturing | Roots Analysis
Industrial Robotics Market to Reach USD 39.03 Billion by 2035, Driven by Rising …
09-04-2025 | Robotics & Automation Press release from: Roots Analysis According to Roots Analysis' latest industry report titled "Industrial Robotics Market: Industry Trends and Global Forecasts, till 2035", the global industrial robotics market is projected to grow from USD 17.64 billion in 2024 to USD 18.80 billion in 2025, reaching USD 39.03 billion by 2035 at a CAGR of 7.5% during the forecast period. To request a quote for this report, visit: https://www.rootsanalysis.com/industrial-robotics-market/request-quote Market Overview Industrial
Targeted Drug Delivery Device Market Size to reach USD 2,153 million by 2035 | Roots Analysis
Targeted Drug Delivery Device Market Size to reach USD 2,153 million by 2035 | R …
According to our latest market report "Targeted Drug Delivery Device Market" by Type of Device, Target Organ, Type of Therapy Delivered, Route of Administration, Therapeutic Area and Key Geographical Regions: Industry Trends and Global Forecasts, Till 2035", the targeted drug delivery device market size is projected to reach USD 2,153 million by 2035 from USD 427 million in 2026, growing at a CAGR of 19.7% in the forecast period, till
The Conjugation and Labeling Services Market is projected to grow at a CAGR of 10.3%, till 2035, claims Roots Analysis
The Conjugation and Labeling Services Market is projected to grow at a CAGR of 1 …
The complexities associated with conjugation of biomolecules and the need for click-chemistry expertise have prompted the pharmaceutical industry to rely on conjugation and labeling service providers To request quote of this report, please visit: https://www.rootsanalysis.com/reports/conjugation-and-labeling-services-market/request-quote.html Roots Analysis is pleased to announce the publication of its recent study, titled, "Conjugation and Labeling Services Market, 2023-2035" The study presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain, across different geographies.

All 5 Releases


More Releases for CRO

Global Veterinary CRO & CDMO Market Size & Trends
According to a new market research report published by Global Market Estimates, the global veterinary CRO & CDMO market is expected to grow at a CAGR of 9.1% from 2023 to 2028. The growing awareness regarding the importance of animal health and welfare has led to increased investments in veterinary pharmaceutical research and development. This awareness is driven by the rising concern for the well-being of pets, livestock, and animals used
Global Contract Research Organization (CRO) Services Market
According to a new market research report published by Global Market Estimates, the Global Contract Research Organization (CRO) Services Market is expected to grow at a CAGR of 10.2% from 2023 to 2028. The growth of the contract research organization (CRO) Services Market is fuelled by factors including the rising preference for outsourcing clinical trials, increasing investments in research and development by pharmaceutical and biopharmaceutical companies, the growing complexities in drug
Contract Research Organization (CRO) Services Market - Efficiency, Expertise, Ex …
Newark, New Castle, USA: The "Contract Research Organization (CRO) Services Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors Contract Research Organization (CRO) Services Market: https://www.growthplusreports.com/report/contract-research-organization-cro-services-market/7630 This latest report
Biopharmaceutical CMO and CRO Market
The Biopharmaceutical CMO and CRO Market crossed US$ 32.25 billion in 2022 and is expected to hit US$ 54.13 billion by 2030, recording a CAGR of 6.5% during the forecast period Pharmaceutical and biotech companies focus on R&D activities to innovate new molecules and therapeutic platforms to deal with chronic diseases and rare ailments; they also extensively invest in R&D activities to develop various therapeutic applications with strong medical and commercial
Pracedo Promote Ellie Copp To CRO
Pracedo, a Mashfrog Group company that provides Salesforce consultancy and digital transformation to charities, NGOs, and enterprise customers, promotes Ellie Copp to Chief Revenue Officer. Pracedo announced Ellie Copp as its new Chief Revenue Officer (CRO). Ellie joined Pracedo in 2019 and most recently held the position of Sales and Marketing Director. As CRO, she will continue to lead the commercial teams by overseeing all revenue-generating activities as Pracedo continues
Partnership factors in sponsor – CRO relationships
Drugs discovered today can realistically cost upwards of 900 million dollars and around 12 years of development to reach a market. CRO’s have been increasingly used by larger pharma to outsource their clinical research, allowing big pharma to shut down in-house R&D, in practice saving money. There have been some issues however with the outsourcing of trials to CROs, including serious relationship break down with negative attitudes, failure to communicate